Objectives: To study the relationship between teicoplanin maintenance dosing and clinical outcomes in adults with MRSA bacteraemia.
Introduction
MRSA is one of the major pathogens in healthcare-associated infections that leads to substantial morbidity and mortality. 1 Concerns raised in the therapy of MRSA bloodstream infection (BSI) with vancomycin, a glycopeptide that has long been regarded as the drug of choice, 2 include treatment failure despite an MIC of vancomycin lying within the susceptible range (i.e. 1 -2 mg/L) 3 and vancomycin MIC creeping upwards. 4, 5 To maximize successful treatment in MRSA infections, the latest clinical practice guidelines issued by the IDSA highlighted the importance of adequate dosing and monitoring serum drug level for keeping serum vancomycin concentrations high enough for serious MRSA infections (e.g. bacteraemia, endocarditis, osteomyelitis, meningitis, pneumonia and/or necrotizing fasciitis) and for infections due to MRSA for which vancomycin MICs are .1 mg/L; in these circumstances, patients' trough serum vancomycin concentrations were recommended to be kept as high as 15 -20 mg/L. 6 Teicoplanin, a naturally occurring lipoglycopeptide that kills Gram-positive cocci by inhibiting the synthesis of cell wall peptidoglycans, has been widely reported to be comparable to vancomycin in efficacy, but has fewer adverse effects than vancomycin. 7 Teicoplanin has been popularly used outside the USA. However, information regarding the relationship between teicoplanin dosing and successful treatment in MRSA infections is largely lacking. Depending upon clinical severity and based on the patient's body weight, dosages of teicoplanin of 6 and 12 mg/kg/day have been conventionally prescribed. A mean daily teicoplanin dose of 4 mg/kg was reported to be associated with higher treatment failure rate when compared with that of 6 mg/kg, and starting 6 mg/kg twice daily might achieve serum concentrations of teicoplanin .10 mg/L the following day. 8 As the antibiotic is substantially protein binding, the effective serum teicoplanin levels in affected patients are often elusive. 9 One report, based on the pharmacokinetics of the antibiotic, recommended universally loading teicoplanin at 6 mg/kg twice daily for 48 h for all infections due to MRSA, and continuing such dosing for severe MRSA infections. 10 Higher teicoplanin MICs (.1.5 mg/L) for the pathogen were reported to be associated with unfavourable outcomes, including higher mortality rate, among MRSA bacteraemic patients who were treated with three teicoplanin loading doses (each of 6 mg/kg, given 12 h apart), followed by teicoplanin 6 mg/kg/24 h. 11 Theoretically, higher teicoplanin doses are indicated for infections due to MRSA for which teicoplanin MICs are high. However, data regarding the relationship between teicoplanin maintenance dosing and clinical outcomes among patients with severe MRSA infection are scarce. To obtain this important information, we conducted a retrospective study to evaluate the outcomes of MRSA bacteraemic patients who received treatment with different teicoplanin maintenance dosing (6 mg/kg/24 h versus 6 mg/kg/12 h) after loading teicoplanin 6 mg/kg/12 h for a total of three doses.
Patients and methods

Patients and study design
This was a retrospective study of MRSA bacteraemic patients admitted between January 2006 and January 2009 to Kaohsiung Chang Gung Memorial Hospital (KCGMH), a 2700 bed primary care and tertiary referral medical centre in southern Taiwan. The study was conducted with a waiver of patient consent approved by the Institutional Review Board of Chang Gung Memorial Hospital (No. 101-1987B). Data on patients with at least one blood culture positive for MRSA were retrieved from the database of the hospital's clinical microbiology laboratory. Vancomycin and teicoplanin were mostly prescribed for MRSA infections at KCGMH, as access to prescriptions of linezolid, daptomycin and tigecycline were restricted to infectious diseases specialists. 12 Susceptibility testing of Staphylococcus aureus isolates was performed on a routine clinical practice basis according to criteria recommended by the CLSI. MRSA was defined as an S. aureus isolate subjected to susceptibility testing using the disc diffusion method in which a disc impregnated with cefoxitin (30 mg) produced an inhibition zone of ≤19 mm (for S. aureus isolates grown in 2006) or ≤21 mm (for S. aureus isolates grown between 2007 and 2009). 13 Patients with a concurrent infection caused by microbe(s) other than MRSA were excluded from this study. If an MRSA was isolated from blood on multiple occasions in the same patient during the study period, only the first episode was counted.
A total of 368 MRSA monobacteraemic patients were found. Their medical charts were reviewed for retrieval of demographic, clinical and laboratory data. Patients who met the following criteria were included for evaluation of the relationship between teicoplanin maintenance dosing and clinical outcomes: (i) age ≥18 years; (ii) normal renal function [estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m 2 ];
14 and (iii) receipt of adequate teicoplanin therapy throughout the treatment course or receipt of vancomycin therapy for ,24 h followed by adequate teicoplanin therapy for .3 days (Figure 1 ). Teicoplanin dosing was prescribed based on the patient's actual body weight. Adequate teicoplanin therapy referred to a loading dose of teicoplanin at 6 mg/kg (maximum 400 mg) given three times 12 h apart, followed by maintenance dosing of 6 mg/kg/12 h or 6 mg/kg/24 h (package insert, Sanofi-Aventis). Maintenance teicoplanin dosing for each of the included patients was prescribed at the discretion of his or her attending physician. No adjunctive antibiotic was found to be used for teicoplanin treatment of MRSA bacteraemia in the included patients. Lee et al.
The clinical severity of the illness at the time of sampling blood for culture was stratified using the modified Pittsburgh bacteraemia score, 15 and was also stratified with regard to whether or not the patient was admitted to an ICU. Sources of bacteraemia were identified according to clinical, microbiological and/or imaging findings. The growth of an MRSA from a patient in whom no apparent infection focus other than blood was identified was defined as bacteraemia with no identified focus of infection; otherwise it was referred to as bacteraemia with an identified focus of infection. Infection foci were described as follows. Pneumonia referred to the presence of clinical symptoms/signs of lower respiratory tract infection, accompanied by consistent radiographic manifestations. 16 Intravenous catheterization was considered the source of bacteraemia if the inserted catheter had been in place for ≥72 h and a culture obtained by rolling the clipped 5 cm distant tip of the removed catheter on culture medium yielded ≥15 colonies of S. aureus or the culture of purulent discharge from the catheter exit grew S. aureus. 17 Endocarditis was diagnosed in an S. aureus bacteraemic patient if consistent histopathology was found in specimens obtained at surgery or valvular vegetation was sonographically revealed regardless of an embolic phenomenon. 18 Endovascular infection referred to an infection involving a vascular graft or endovascular device, which was clinically diagnosed and histopathologically proven. Osteomyelitis in an S. aureus bacteraemic patient referred to bone infection, which was diagnosed based on clinical manifestations coupled with consistent histopathological and/or radiographical findings, regardless of an S. aureus isolated from the infection site. Urinary tract infection was considered to be caused by S. aureus when the microbe was the only identified pathogen that yielded ≥10 5 cfu/mL in urine culture. Soft tissue infection was considered to be caused by S. aureus when the microbe grew from the specimen sampled from the affected site. An adverse event referred to an undesired effect that happened after using teicoplanin and improved after discontinuation of the antibiotic.
Efficacy assessment
An early clinical response referred to the clinical response assessed on day 7 after initiating teicoplanin therapy, while a final clinical response referred to the response evaluated upon completion of teicoplanin therapy. At early clinical response assessment, patients were evaluated for the presence of (i) septic shock, (ii) persistent fever, (iii) persistent leucocytosis and/ or (iv) persistent bacteraemia on day 7; a favourable and an unfavourable early clinical response referred to the absence and presence of any of these findings, respectively.
The final clinical response was categorized as cure, improvement or treatment failure. Cure was defined as the disappearance of clinical symptoms/signs coupled with a subsequent negative blood culture and no requirement for further antibiotic therapy. Improvement was defined as the relief of symptoms/signs, but, based on clinical adjustment, with a requirement for additional antibiotic treatment. Treatment failure referred to (i) clinical progression or relapse of sepsis that had previously clinically improved, (ii) fatality and/or (iii) culture of blood sampled at the end of teicoplanin treatment remaining positive for MRSA. Cure and improvement were grouped as a favourable final clinical response, whereas treatment failure referred to an unfavourable final clinical response. BSI-related mortality was defined as fatality in an MRSA bacteraemic patient with clinically unrelenting sepsis. 19 Thirty-day in-hospital mortality was defined as allcause mortality occurring within 30 days of hospitalization after the onset of MRSA bacteraemia. In a total of 38 patients with an unfavourable clinical response to teicoplanin, antibiotic therapy was switched. Among the 21 (55.3%) patients who switched to daptomycin treatment with an overall favourable final clinical response rate of 71.4%, 12 were found to have osteomyelitis, 6 infective endocarditis and 3 catheter-related bacteraemia. Of the 12 patients (31.6%) who switched to linezolid therapy with an overall favourable final clinical response rate of 58.3%, 9 had pneumonia, 2 bacteraemia with no identified focus of infection and 1 concurrent pneumonia and soft tissue infection. Among the five (13.1%) patients who switched to tigecycline treatment with an overall favourable final clinical response rate of 20.0%, three had bacteraemia with no identified focus of infection and two experienced concurrent soft tissue infection and urinary tract infection.
Statistical analysis
Discussion
The use of AUC/MIC as a surrogate marker of the clinical efficacy of glycopeptide in the treatment of infection due to MRSA is Teicoplanin maintenance dosing in MRSA bacteraemia Bold formatting indicates statistical significance. Lee et al.
controversial, and this is especially true when the AUC/MIC is used in the assessment of the clinical efficacy of teicoplanin. 20 The trough plasma concentration (C min ) of teicoplanin has, however, been widely accepted as a determinant of the clinical outcomes of MRSA-infected patients. 8,21 -23 One early report on teicoplanin treatment of infections caused by staphylococci with a teicoplanin MIC 90 ≤1 mg/L revealed a significantly higher cure rate in patients with a C min .25 mg/L than in those with a C min ,5 mg/ L (90% versus 20%). 21 A teicoplanin C min .10 mg/L is accepted as a target concentration for therapy in combination with other antibiotic(s), and a higher target teicoplanin C min (.20 mg/L) is recommended for therapeutic scenarios such as teicoplanin monotherapy and the treatment of endocarditis and bone/ prosthetic infection due to S. aureus. 8, 22, 23 The significantly higher favourable final clinical response rates found in endocarditis and pneumonia patients who received higher teicoplanin maintenance dosing in our series are in agreement with previous reports that suggested higher teicoplanin dosing for such severe MRSA infections are indicated. 8, 10, 22, 23 Upward-creeping MICs of teicoplanin for S. aureus isolates have been widely found as a result of the prolonged and intensive exposure of microbes to glycopeptides. 24, 25 Although conflicting conclusions on whether a higher teicoplanin MIC leads to higher chances of MRSA bacteraemia-related fatality in teicoplanintreated patients were drawn by different studies, what was common to these investigations was the finding that comorbidities Remarkably, recently published data disclosed that among those who received three teicoplanin loading doses of 400 mg/12 h and then 400 mg/day, bacteraemic patients with higher teicoplanin MICs (.1.5 mg/L) for the culprit MRSA had higher rates of unfavourable outcomes and BSI-related mortality, 11 and pneumonia patients with higher teicoplanin MICs (.2 mg/L) for the pathogenic MRSA had a higher treatment failure rate. 27 These reports, in agreement with others, suggested that high teicoplanin doses are needed to rapidly attain a higher C min by appropriate antibiotic loading in patients with severe infection caused by MRSA. 11, 27, 28 In a pharmacokinetics study, Brink et al. 10 reported that after using 400 mg of teicoplanin and 12 h later as loading doses (day 1), patients were divided into two groups: those receiving 6 mg/ kg/day (once daily group) and those who continued receiving teicoplanin 6 mg/kg/12 h (twice daily group); the two target C min values (≥10 and ≥20 mg/L) were only achieved by day 4 in the once daily group and in the twice daily group, respectively. However, the mean C min in the twice daily group was ≥10 mg/L by day 2. 10 The above-mentioned data well explain the significantly higher rates of favourable early clinical response and final clinical response and lower BSI-related mortality rate in Group 2 in our series compared with those in Group 1, in which low maintenance teicoplanin doses were used, because C min ≥20 mg/L could only be anticipated in Group 2 by day 4, while C min ≥10 mg/L could be expected 2 days earlier in Group 2 (day 2). Of note, increased serum antibiotic levels but not drug toxicity was reported in patients in whom maintenance teicoplanin was switched from 400 to 600 mg/day. 29 The limitations of our study included biases inherent in retrospective studies, the lack of MLST for the MRSA isolates, the change of adopted MIC cut-off for cefoxitin in defining MRSA using the disc diffusion method recommended by CLSI during the study period, the lack of analysis of teicoplanin MIC values for the pathogens and the lack of analysis of serum teicoplanin levels of the involved patients. Teicoplanin MICs for MRSA isolates of different sequence type might differ. 26 Nevertheless, the theoretically rapid attainment of C min of teicoplanin, leading to better clinical outcomes in MRSA infections, was in agreement with the outcomes published in the literature. 8,21 -23,30 The importance of loading doses of teicoplanin in the treatment of MRSA infection was well documented in previous reports, 8, 21, 30 and our report highlights that appropriate teicoplanin maintenance dosing is equally important.
Because of the complex pharmacokinetics of teicoplanin, 9, 31, 32 serum concentrations of the antibiotic are often elusive and, as a result, a great variety of dosing regimens, including differing loading dosing and/or differing maintenance dosing, has been reported. 8, 10, 30 This may confuse clinicians rather than facilitate the prescription of appropriate teicoplanin dosing regimens. To make the recommended effective teicoplanin regimen simple and prescriber-friendly, we propose, based on our data, a teicoplanin dosing regimen of 6 mg/kg/12 h (maximal 400 mg/12 h) for MRSA bacteraemic patients with normal renal function, without emphasizing loading dosing and maintenance dosing, as an imaginary line can be drawn between the first three teicoplanin doses and the subsequent teicoplanin doses, regarding the former as loading doses and the latter as maintenance doses.
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